DNA methylation as determinant of myelodysplastic syndromes treatment with hypomethylating agents (WP2)
Rationale and objectives
Hypomethylating agents (HMAs) are the current best care for myelodysplastic syndromes (MDS) patients not eligible for transplantation. However, treatment success is partial and we are lacking biomarkers and combinatorial drug targets.
The project's objectives are:
• To characterize evolution of DNA methylation patterns in bone marrow samples during HMA therapy.
• To correlate DNA methylation patterns at the population and single-cell level with response and therapy failure.
• To study the potential synergy of natural and experimental genetic perturbation of chromatin modifiers with HMAs.
Josep Carreras Leukaemia Research Institute (Spain, 3 months), MLL Munich Leukemia Laboratory (Germany, 2 months).
PhD in Genetics, Oncology and Clinical Medicine, UniFi, Italy.